Physician profile
Jinahn E Kim
NPI 1922057702
$22,592.29
in general payments reported to CMS, 2019-2025
56 companies · $2,233 in 2025
The $2,233 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,365 · 2020: $3,104 · 2021: $3,743 · 2022: $3,377 · 2023: $3,624 · 2024: $3,147 · 2025: $2,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,842 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,842.23 |
| Education | $161.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,268.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,257.02 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,882.64 | 2019-2025 | |
| Amarin Pharma, INC. | $1,329.51 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $1,290.51 | 2019-2023 | |
| Amgen INC. | $1,187.03 | 2019-2025 | Evenity, Repatha, Otezla |
| Gilead Sciences, INC. | $968.17 | 2019-2025 | Vemlidy |
| Radius Health, INC. | $924.29 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $916.69 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $896.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $843.34 | 2019-2025 | |
| Astellas Pharma US INC | $720.32 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $718.20 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $676.87 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $474.42 | 2019-2025 | Ztlido |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinahn Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.